UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Annals of oncology, 2021-05, Vol.32 (5), p.609-619

2021

Volltextzugriff (PDF)

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Annals of oncology, 2019-09, Vol.30 (9), p.1487-1495

2019

Volltextzugriff (PDF)

Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery

Annals of internal medicine, 2001-11, Vol.135 (10), p.847

2001

Volltextzugriff (PDF)

Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples

Annals of oncology, 2018-10, Vol.29, p.viii32-viii32

2018

Volltextzugriff (PDF)

Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery

Annals of surgery, 2000-08, Vol.232 (2), p.242-253

2000

Volltextzugriff (PDF)

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Annals of oncology, 2020-11, Vol.31, p.S1315-S1316

2020

Volltextzugriff (PDF)

A self-administered screening instrument for psychogenic nonepileptic seizures

Neurology, 2009-05, Vol.72 (19), p.1646-1652

2009

Volltextzugriff (PDF)

Relation between literacy and HIV treatment knowledge among patients on HAART regimens

AIDS care, 2005-10, Vol.17 (7), p.863-873

2005

Volltextzugriff (PDF)

P-104 Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy

Annals of oncology, 2021-07, Vol.32, p.S133-S134

2021

Volltextzugriff (PDF)

103PPrevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era

American journal of respiratory and critical care medicine, 2000-04, Vol.161 (4), p.1081-1086

2000

Volltextzugriff (PDF)

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Annals of oncology, 2020-11, Vol.31, p.S1317-S1317

2020

Volltextzugriff (PDF)

SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study

Annals of oncology, 2019-11, Vol.30, p.ix66-ix67

2019

Volltextzugriff (PDF)

GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study

Annals of oncology, 2019-11, Vol.30, p.ix65-ix66

2019

Volltextzugriff (PDF)

GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Annals of oncology, 2019-10, Vol.30, p.v322

2019

Volltextzugriff (PDF)

836TiP - GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Annals of oncology, 2019-10, Vol.30, p.v322-v322

2019

Volltextzugriff (PDF)

836TiPGLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Relationship between Health Insurance and Medical Care for Patients Hospitalized with Human Immunodeficiency Virus—Related Pneumocystis carinii Pneumonia, 1995–1997: Medicaid, Bronchoscopy, and Survival

Clinical infectious diseases, 2003-12, Vol.37 (11), p.1549-1555

2003

Volltextzugriff (PDF)

Racial variation in the use of laparoscopic cholecystectomy in the Department of Veterans Affairs Medical System

Journal of the American College of Surgeons, 1999-06, Vol.188 (6), p.604-622

1999

Volltextzugriff (PDF)

Health literacy, social support, and health: a research agenda

Social science & medicine (1982), 2004-04, Vol.58 (7), p.1309-1321

2004

Volltextzugriff (PDF)

Erratum

Bioethics, 2015-01, Vol.29 (1), p.56-56

2015

Volltextzugriff (PDF)

Erratum

Bioethics, 2015-01, Vol.29 (1), p.56-56

2015

Volltextzugriff (PDF)

Erratum

Bioethics, 2015-01, Vol.29 (1), p.56-56

2015

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(102)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(34)
Humans
(31)
Male
(20)
Female
(18)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Middle Aged
(14)
Aged
(13)
Engineering
(12)
Technology
(12)
Adult
(10)
Engineering, Electrical & Electronic
(10)
Neural Networks
(9)
General & Internal Medicine
(7)
Oncology
(7)
Literacy
(6)
Public, Environmental & Occupational Health
(6)
Social Support
(6)
Telecommunications
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery

Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples

Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

A self-administered screening instrument for psychogenic nonepileptic seizures

Relation between literacy and HIV treatment knowledge among patients on HAART regimens

P-104 Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy

103PPrevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples

A new preadmission staging system for predicting inpatient mortality from HIV-associated Pneumocystis carinii pneumonia in the early highly active antiretroviral therapy (HAART) era

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study

GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study

GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

836TiP - GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

836TiPGLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Relationship between Health Insurance and Medical Care for Patients Hospitalized with Human Immunodeficiency Virus—Related Pneumocystis carinii Pneumonia, 1995–1997: Medicaid, Bronchoscopy, and Survival

Racial variation in the use of laparoscopic cholecystectomy in the Department of Veterans Affairs Medical System

Health literacy, social support, and health: a research agenda

Erratum

Erratum

Erratum

Suchergebnisse filtern